To the Editor The recently published Original Investigation by Theelen and colleagues regarding the PEMBRO-RT trial1 has brought promising and encouraging results for the efficacy and safety of stereotactic body radiotherapy (SBRT) followed by treatment with pembrolizumab compared with treatment with pembrolizumab alone in patients with advanced non–small cell lung cancer (NSCLC) that progressed after at least 1 regimen of chemotherapy, though the primary end point was not reached. However, in addition to the perspectives and limitations mentioned by the authors, several other issues deserve attention.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Yang X, Men Y, Hui Z. Going Beyond Results of the PEMBRO-RT Trial. JAMA Oncol. Published online November 21, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.5028
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: